-
VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-200932024-11-01
-
VOLUNTARY ANNOUNCEMENT - AMEILE PHASE III CLINICAL TRIAL MET THE PRIMARY ENDPOINT IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NSCLC2024-10-22
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 20242024-10-02
-
Notification Letter and Request Form to Non-registered Holders2024-09-26
-
Notification Letter and Reply Form to Registered Shareholders2024-09-26
-
INTERIM REPORT 20242024-09-26
-
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 20242024-09-02
-
ADJUSTMENT TO CONVERSION PRICE OF THE CONVERTIBLE BONDS2024-08-27
-
INTERIM DIVIDEND FOR THE SIX MONTHS ENDED JUNE 30, 20242024-08-27
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 20242024-08-27
-
VOLUNTARY ANNOUNCEMENT - B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION2024-08-20
-
VOLUNTARY ANNOUNCEMENT - THE FOURTH NEW DRUG APPLICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2024-08-19
